ZFP14 Inhibitors
Chemical inhibitors of ZFP14 can lead to a reduction in its functional activity through various biochemical pathways. Palbociclib, a selective inhibitor of CDK4/6, plays a crucial role in halting the cell cycle in the G1 phase by reducing the phosphorylation of the retinoblastoma protein, which may prevent ZFP14 from fulfilling its cell cycle-related roles. Similarly, the proteasome inhibitor MG132 can cause the accumulation of ubiquitinated proteins, potentially interfering with ZFP14's ability to bind to its targets due to the heightened competition or feedback inhibition from an increased pool of substrates. LY294002 and Wortmannin both act as PI3K inhibitors, blocking a pathway known to influence transcription; by doing so, they can decrease ZFP14's activity on its target genes.
Further, U0126 and PD98059, which are specific inhibitors of MEK1/2, prevent the activation of ERK-a kinase that may be involved in the phosphorylation events necessary for ZFP14 activation or interaction with its cofactors. Inhibition of this pathway indicates a subsequent decrease in ZFP14 activity. SB203580 and SP600125 target the MAPK pathways, with SB203580 inhibiting p38 MAPK and SP600125 inhibiting JNK. Both p38 MAPK and JNK are known to affect the activity of various transcription factors, and their inhibition can result in reduced functional activity of ZFP14. Y-27632, a ROCK inhibitor, disrupts cytoskeletal dynamics, which can be essential for ZFP14 to access or modify chromatin structures effectively. Rapamycin, an mTOR inhibitor, can disrupt protein synthesis and other processes crucial for ZFP14's activity. Triciribine, by inhibiting AKT, can similarly lead to a decrease in ZFP14's activity if AKT signaling is required for its function. Lastly, Dasatinib, as a broad-spectrum tyrosine kinase inhibitor, may block specific tyrosine kinase pathways that are essential for the functional activity of ZFP14.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of CDK4/6, which are crucial for cell cycle progression. Inhibition of CDK4/6 can lead to reduced phosphorylation of the retinoblastoma protein (pRb), thereby inducing G1 phase arrest. If ZFP14 is involved in cell cycle regulation, inhibiting CDK4/6 would arrest cells in G1, indirectly preventing ZFP14 from exerting its functions during the cell cycle. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins. If ZFP14 is regulated by proteasomal degradation, MG132 would result in the accumulation of ZFP14 substrates, which could hinder ZFP14’s ability to bind its targets due to competition or feedback inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor which blocks the PI3K/AKT pathway. Since the PI3K/AKT pathway is involved in numerous cellular functions including transcription, if ZFP14 is regulated by PI3K signaling, LY294002 would inhibit the pathway, potentially reducing ZFP14's activity on its target genes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, key components of the MAPK/ERK pathway. By inhibiting MEK, U0126 prevents the activation of ERK, which may be involved in phosphorylation events that activate ZFP14 or its cofactors, leading to an inhibition of ZFP14's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway can regulate various transcription factors and if ZFP14 is activated by p38 MAPK-mediated phosphorylation, then SB203580 would inhibit this activation, leading to a reduction in ZFP14’s activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the stress-activated MAPK pathway. JNK can influence the activity of numerous transcription factors; thus, if ZFP14 function is modulated by JNK signaling, SP600125 would inhibit this influence, leading to decreased ZFP14 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor, and ROCK is involved in cytoskeletal arrangement. If ZFP14 is associated with transcriptional regulation that depends on cytoskeletal dynamics, inhibiting ROCK with Y-27632 could impair ZFP14's ability to access or modify chromatin. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR signaling affects many cellular processes including protein synthesis. Inhibition of mTOR by Rapamycin could disrupt processes that are necessary for the full activity of ZFP14, therefore functionally inhibiting it. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, if ZFP14's function is modulated by PI3K activity, Wortmannin would inhibit this pathway, potentially leading to a decrease in ZFP14's functional activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine is an inhibitor of AKT. If ZFP14 requires AKT signaling for its full functional activity, blocking AKT with Triciribine would lead to a decrease in ZFP14's activity. | ||||||